Publications found:
705
Sort by:
US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025
US$ 2,400.00
... Breast Cancer Drug Market. US breast cancer drug market has high potency of growth with 42 drugs being commercially available and more than 300 of them being in the clinical pipeline ... . It is definitive that the market will grow due to the increase in prevalence of breast cancer and large ...
April 2019
700 pages
Global Malignant Melanoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
US$ 3,000.00
... Drug Market Overview Dosage, Price & Patent Insight Global Malignant Melanoma Drug Clinical Pipeline: 197 Drugs Marketed Malignant Melanoma Drug Clinical Insight: 25 Drugs Sales Analysis of Global Melanoma Therapeutics Regional Analysis of the Melanoma Drug Market Melanoma occurs due to mutations in the skin ...
April 2018
470 pages
Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022
US$ 2,400.00
... of Radioimmunotherapy Clinical Status of Radioimmunotherapy in Various Cancer Therapy Emerging Opportunities in the Radioimmunotherapy Segment Patent, Dosage & Price Analysis Antibodies in Radioimmunotherapy Global Radioimmunotherapy Clinical Pipeline: 68 Drugs Clinical Pipeline analysis by Phase Cancer ...
March 2018
200 pages
Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024
US$ 2,400.00
... analysis of 10 cancer tubulin inhibitors commercially available in the market. “Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” Report highlights: Clinical Insight on 70 Tubulin Inhibitors in pipeline Dosage & Price Analysis of 10 Commercialized Drugs Patent ...
February 2018
225 pages
Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022
US$ 2,200.00
... 45 CDK inhibitors are in various phases of clinical pipeline. “Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022” report highlights: Selectivity & Working Mechanism of a Cancer CDKs Inhibitor Recent Advances in the CDKs Related Cancer Therapy Global Cancer CDK Inhibitors Clinical Trials ...
November 2017
150 pages
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
US$ 2,400.00
... Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” Highlights: Mechanism of Action of JAK/STAT Inhibitors Global Cancer JAK/STAT Inhibitor Market Outlook Global JAK/STAT Inhibitor Market Opportunity: US$ 4 Billion Global JAK/STAT Inhibitor in Pipeline: 27 Drugs Global Cancer JAK ...
October 2017
190 pages
CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023
US$ 3,300.00
... cancer cells. “CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights: Market Opportunity Assessment: More than US$ 60 Billion by 2023 Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs Clinical & Licensing Insight on 184 CD Antigens in Clinical ...
October 2017
500 pages
Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022
US$ 2,400.00
... Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report highlights: Impetus of Antibody Drug Conjugates Mechanism of Cancer Antibody Drug Conjugates Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview Marketed Cancer Antibody Drug Conjugate Clinical Insight Global Cancer Antibody ...
May 2017
420 pages
Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
US$ 2,400.00
... cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market. Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies ...
April 2017
280 pages
Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022
US$ 2,400.00
... immune checkpoint inhibitors in the market. “Global Immune Check Point Inhibitors Market & Clinical Pipeline Insight 2022” report highlights: Introduction & Mechanism of Action of Immune Checkpoint Inhibitors CTLA 4, PD-1 & PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints ...
March 2017
222 pages